A recent meta-analysis showed that stage I CRC, in particular T1 CRC, has a lower FIT sensitivity than later stages (52), although this meta-analysis did not evaluate very low thresholds (<10 μg Hb/g feces) and stage-specific sensitivity by tumor location. This evidence concerns the gene GSTM1 and colorectal carcinoma.